



## PRESS RELEASE

### For Immediate Release

## **CORGENIX SUBMITS FDA PREMARKET NOTIFICATION OF ASPIRINWORKS<sup>®</sup> TEST KIT**

### *NEW DIAGNOSTIC PRODUCT TO BE USED IN ASSESSING ASPIRIN EFFECTIVENESS*

DENVER, COLORADO — July 20, 2006 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has submitted a Premarket Notification (510k) to the U.S. Food and Drug Administration (FDA) for the Company's AspirinWorks<sup>®</sup> Test Kit, the Company's newest diagnostic product for cardiovascular disease.

The AspirinWorks<sup>®</sup> Test Kit is a simple urine test that measures an individual's response to aspirin dosage and allows physicians to adjust the dosage or recommend alternative therapy. Recent reports indicate that up to 25 percent of individuals may be non-responsive to aspirin's benefits, and are more than three times more likely to die from heart disease.

"The submission of the AspirinWorks<sup>®</sup> 510(k) to the FDA is another important milestone for our Company. We have significant expectations for this product due to the strong interest it has already piqued worldwide," said Douglass Simpson, Corgenix President and Chief Executive Officer. "This new test kit will be sold through our U.S. sales force once we have clearance."

The AspirinWorks<sup>®</sup> Test Kit is a quantitative enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B<sub>2</sub> (11dhTxB<sub>2</sub>) in human urine, which aids in the assessment of the response to aspirin. The kit was launched internationally in July at the 52nd Annual Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis held in Oslo, Norway.

The AspirinWorks<sup>®</sup> product was developed in conjunction with Corgenix' strategic partners, Creative Clinical Concepts (CCC), a Denver based biotechnology company, and Cayman Chemical Company (Cayman), an Ann Arbor, Michigan manufacturer of biochemical research products. Corgenix and CCC have previously announced collaboration with McMaster University (McMaster), Hamilton, Ontario. Under terms of a license agreement with McMaster, Corgenix and CCC have exclusive worldwide rights to the proprietary technology owned by McMaster for the development, manufacturing and marketing of innovative diagnostic tests specific to the pathway by which aspirin acts on platelets.

The McMaster technology includes several patents pending in the United States, Canada and Europe, and has received notice of allowance of the first of the U.S. patent applications. In

addition to licensing the McMaster technology, Corgenix also has a U.S. patent pending on the AspirinWorks<sup>®</sup> product.

## **About Corgenix Medical Corporation**

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at [www.corgenix.com](http://www.corgenix.com).

*Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.*

### Company Contact:

Corgenix Medical Corp  
William Critchfield, Senior VP and CFO  
(303) 453-8903  
Email: [wcritchfield@corgenix.com](mailto:wcritchfield@corgenix.com)

### Investor Contact:

The Investor Relations Group  
Dian Griesel/ Erika Moran  
Phone: (212) 825-3210  
Fax: (212) 825-3229

### Media Contact:

Dan Snyders  
Vice President, Public Relations Supervisor  
Armada Medical Marketing  
4840 W. 29th Avenue  
Denver CO 80212  
T: 303-623-1190 x 230  
F: 303-623-1191  
[dan@armadamedical.com](mailto:dan@armadamedical.com)